Sylvie Baier

Sylvie Baier

Auto-generated profile, based on publicly available information

Sylvie Baier

Institute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Nucleic Acids Research
Verified
Journal Article
Open access
AMAndreas Maier
Andreas Maier
MHMichael Hartung
Michael Hartung
MAMark Abovsky
Mark Abovsky
KAKlaudia Adamowicz
Klaudia Adamowicz
GBGary Bader
Gary Bader
Jan BaumbachJan Baumbach
Jan Baumbach
In recent decades, the development of new drugs has become increasingly expensive and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and network medicine tools have emerged to identify potential drug repurposing candidates. However, these tools often require complex installation and lack intuitive visual network mining capabilities. To tackle these challenges, we introduce Drugst.One, a platform that assists specialized computational medicine tools in becoming user-friendly, web-based utilities for drug repurposing. With just three lines of code, Drugst.One turns any systems biology software into an interactive web tool for modeling and analyzing complex protein-drug-disease networks. Demonstrating its broad adaptability, Drugst.One has been successfully integrated with 21 computational systems medicine tools. Available at https://drugst.one, Drugst.One has significant potential for streamlining the drug discovery process, allowing researchers to focus on essential aspects of pharmaceutical treatment research.

23 August 2024 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MHMarkus Hoffmann
Markus Hoffmann
JPJulian M Poschenrieder
Julian M Poschenrieder
MIMassimiliano Incudini
Massimiliano Incudini
SBSylvie Baier
Sylvie Baier
AFAmelie Fritz
Amelie Fritz
DBDavid B Blumenthal
David B Blumenthal
Most heritable diseases are polygenic. To comprehend the underlying genetic architecture, it is crucial to discover the clinically relevant epistatic interactions (EIs) between genomic single nucleotide polymorphisms (SNPs) ( 1–3). Existing statistical computational methods for EI detection are mostly limited to pairs of SNPs due to the combinatorial explosion of higher-order EIs. With NeEDL (network-based epistasis detection via local search), we leverage network medicine to inform the selection of EIs that are an order of magnitude more statistically significant compared to existing tools and consist, on average, of five SNPs. We further show that this computationally demanding task can be substantially accelerated once quantum computing hardware becomes available. We apply NeEDL to eight different diseases and discover genes (affected by EIs of SNPs) that are partly known to affect the disease, additionally, these results are reproducible across independent cohorts. EIs for these eight diseases can be interactively explored in the Epistasis Disease Atlas (https://epistasis-disease-atlas.com). In summary, NeEDL demonstrates the potential of seamlessly integrated quantum computing techniques to accelerate biomedical research. Our network medicine approach detects higher-order EIs with unprecedented statistical and biological evidence, yielding unique insights into polygenic diseases and providing a basis for the development of improved risk scores and combination therapies.

9 November 2023 in medRxiv
Verified
Preprint
Open access
PDF file
MHMarkus Hoffmann
Markus Hoffmann
JPJulian M. Poschenrieder
Julian M. Poschenrieder
MIMassimiliano Incudini
Massimiliano Incudini
SBSylvie Baier
Sylvie Baier
AFAmelie Fitz
Amelie Fitz
DBDavid B. Blumenthal
David B. Blumenthal
Most heritable diseases are polygenic. To comprehend the underlying genetic architecture, it is crucial to discover the clinically relevant epistatic interactions (EIs) between genomic single nucleotide polymorphisms (SNPs) 1–3 . Existing statistical computational methods for EI detection are mostly limited to pairs of SNPs due to the combinatorial explosion of higher-order EIs. With NeEDL ( ne twork-based e pistasis d etection via l ocal search), we leverage network medicine to inform the selection of EIs that are an order of magnitude more statistically significant compared to existing tools and consist, on average, of five SNPs. We further show that this computationally demanding task can be substantially accelerated once quantum computing hardware becomes available. We apply NeEDL to eight different diseases and discover genes (affected by EIs of SNPs) that are partly known to affect the disease, additionally, these results are reproducible across independent cohorts. EIs for these eight diseases can be interactively explored in the Epistasis Disease Atlas ( https://epistasis-disease-atlas.com ). In summary, NeEDL is the first application that demonstrates the potential of seamlessly integrated quantum computing techniques to accelerate biomedical research. Our network medicine approach detects higher-order EIs with unprecedented statistical and biological evidence, yielding unique insights into polygenic diseases and providing a basis for the development of improved risk scores and combination therapies.

29 April 2026 in Critical Reviews in Food Science and Nutrition
Verified
Journal Article
Open access
CHChristoph Hassenberg
Christoph Hassenberg
CMCarina I. Mack
Carina I. Mack
CFCLAUDIA FAVARI
CLAUDIA FAVARI
SBSylvie Baier
Sylvie Baier
Ramon EstruchRamon Estruch
Ramon Estruch
SKSabine E. Kulling
Sabine E. Kulling
Dietary assessment traditionally relies on self-reporting methods such as food frequency questionnaires (FFQ), dietary recalls, and food diaries. These approaches have well-known limitations due to...

3 November 2026 in JMIR AI
Verified
Journal Article
Open access
SSSimon Süwer
Simon Süwer
KBKester Bagemihl
Kester Bagemihl
SBSylvie Baier
Sylvie Baier
LDLucia Dicunta
Lucia Dicunta
MLMarkus List
Markus List
AMAndreas Maier
Andreas Maier
Background: Repurposing approved drugs offers a time- and cost-effective alternative to traditional drug development. However, in silico prediction of repurposing candidates is challenging and requires the effective collaboration of specialists in various fields, including pharmacology, medicine, biology, and bioinformatics. Fragmented, specialized algorithms and tools often address only narrow aspects of the overall problem. Heterogeneous, unstructured data landscapes require the expertise of specialized users. Hence, diverse data sources might not integrate smoothly across workflows. Objective: We aimed to develop an integrated, natural language–driven system that enables domain experts to conduct complex network-based drug repurposing analyses by integrating heterogeneous biomedical data sources and specialized bioinformatics methods within a unified workflow. Methods: With ChatDRex, we present a conversation-based, multi-agent system that facilitates the execution of complex bioinformatic analyses aiming for network-based drug repurposing prediction. It builds on the integrated systems medicine knowledge graph NeDRexDB. ChatDRex provides natural language access to its extensive biomedical knowledge base. It integrates bioinformatics agents for network analysis, literature mining, and drug repurposing. These are complemented by agents that evaluate functional coherence for in silico validation. Its flexible multi-agent design assigns specific tasks to specialized agents, including query routing, data retrieval, algorithm execution, and result visualization. A dedicated reasoning module keeps the user in the loop and allows for hallucination detection. Results: ChatDRex operationalizes complex network-based drug repurposing workflows through conversational interaction, integrating biomedical knowledge access with algorithm execution and validation-oriented assessments. Its modular multi-agent architecture enables scalable task specialization across retrieval, analysis, validation, and visualization, while the reasoning module provides transparency and safeguards against unreliable outputs. Conclusions: By enabling researchers with limited computational expertise to control complex analyses with natural language, ChatDRex could democratize access to bioinformatics as an important resource for drug repurposing. It could enable clinical experts to generate hypotheses and explore drug repurposing opportunities, ultimately accelerating the discovery of novel therapies and advancing personalized medicine and translational research.